UK announces full inquiry into medicines shortages
This article was originally published in SRA
Executive Summary
UK medicine shortages of brand name prescription drugs, which the pharmaceutical industry has attributed to parallel trade, are to be the subject of a major inquiry, says the All-Party Pharmacy Group, made up of members of the House of Commons and the House of Lords from various political parties1.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.